Grant of Options

Inspiration Healthcare Group PLC
04 July 2024
 

4 July 2024

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Grant of Options

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, announces that it has granted a total of 672,415 nil cost options over ordinary shares of 10 pence each in the capital of the Company ("Options") under the Inspiration Healthcare Group Long Term Incentive Plan (the "LTIP"), to Alan Olby (Chief Financial Officer) and Brook Nolson (Chief Operating Officer), both of whom are Persons Discharging Managerial Responsibilities ("PDMRs") as detailed below.

The Options are exercisable at nil cost and are subject to Remuneration Committee discretion over a two-year period ending on 2 July 2026.

 For further information:

Inspiration Healthcare Group plc

                        Tel: +44 (0)330 175 0000

Roy Davis, Executive Chair and Interim CEO


Alan Olby, Chief Financial Officer




Liberum (Nominated Adviser & Broker)

                        Tel: +44 (0)20 3100 2000

Richard Lindley, Will King, Joshua Borlant


 


Walbrook PR Ltd (Media and Investor Relations)

                        Tel: +44 (0)20 7933 8700

Anna Dunphy/Stephanie Cuthbert/Louis Ashe-Jepson


 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1. Alan Olby

2.  Brook Nolson

2

Reason for the notification

a)

Position/status

1.  PDMR (CFO)

2.  PDMR (COO)

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Inspiration Healthcare Group plc

 

b)

LEI

213800GKFT3ENAPMDL15

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Options over Ordinary Shares of 10p each in the capital of the Company

ISIN: GB00BXDZL105

b)

Nature of the transaction

Grant of Options under the Long Term Incentive Plan

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

Volume(s)

1. Nil

2. Nil

1. 356,537

2. 315,878



 

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

 
N/A - single transaction

 

e)

Date of the transaction

3 July 2024

f) 

Place of the transaction

Outside of a trading venue

 

About Inspiration Healthcare Group plc 

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy.  In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

The Company operates in the UK from its world-class Manufacturing and Technology Centre in Croydon, South London and in the USA from its facility in Melbourne, Florida.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100